Ultimately, effective targeting of HIF-1α, along with other potential biomarkers, may enhance patient outcomes, reduce mortality, and alleviate the socioeconomic burden of endometrial cancer (EC) in individuals with type 2 diabetes mellitus (T2DM), paving the way for more precise treatment strategies. The gene discussed is HIF1A; the disease is endometrial cancer.